[go: up one dir, main page]

TN2010000063A1 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) - Google Patents

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)

Info

Publication number
TN2010000063A1
TN2010000063A1 TNP2010000063A TN2010000063A TN2010000063A1 TN 2010000063 A1 TN2010000063 A1 TN 2010000063A1 TN P2010000063 A TNP2010000063 A TN P2010000063A TN 2010000063 A TN2010000063 A TN 2010000063A TN 2010000063 A1 TN2010000063 A1 TN 2010000063A1
Authority
TN
Tunisia
Prior art keywords
pcsk9
antigen binding
binding proteins
proprotein convertase
convertase subtilisin
Prior art date
Application number
TNP2010000063A
Other languages
English (en)
Inventor
Simon Mark Jackson
Nigel Pelham Clinton Walker
Derek Evan Piper
Bei Shan
Wenyan Shen
Joyce Chi Yee Chan
Chadwick Terence King
Randal Robert Ketchem
Christopher Mehlin
Teresa Arazas Carabeo
Qiong Cao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39951467&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2010000063A1 publication Critical patent/TN2010000063A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
TNP2010000063A 2007-08-23 2010-02-05 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) TN2010000063A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95766807P 2007-08-23 2007-08-23
US896507P 2007-12-21 2007-12-21
US1063008P 2008-01-09 2008-01-09
US8613308P 2008-08-04 2008-08-04
PCT/US2008/074097 WO2009026558A1 (fr) 2007-08-23 2008-08-22 Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (pcsk9)

Publications (1)

Publication Number Publication Date
TN2010000063A1 true TN2010000063A1 (en) 2011-09-26

Family

ID=39951467

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000063A TN2010000063A1 (en) 2007-08-23 2010-02-05 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)

Country Status (42)

Country Link
US (27) US8030457B2 (fr)
EP (3) EP3202791A1 (fr)
JP (7) JP5441905B2 (fr)
KR (10) KR20180035947A (fr)
CN (8) CN104311667A (fr)
AR (1) AR068011A1 (fr)
AU (1) AU2008288791B2 (fr)
BR (2) BR122018012430B8 (fr)
CA (1) CA2696252C (fr)
CL (1) CL2008002495A1 (fr)
CO (1) CO6230997A2 (fr)
CR (1) CR11328A (fr)
CY (3) CY1117940T1 (fr)
DE (2) DE202008018562U1 (fr)
DK (2) DK3666797T5 (fr)
EA (1) EA032106B1 (fr)
ES (3) ES2573258T5 (fr)
FI (2) FI3666797T3 (fr)
FR (1) FR16C0025I2 (fr)
HR (2) HRP20230503T3 (fr)
HU (4) HUE062493T2 (fr)
IL (5) IL304868A (fr)
JO (1) JOP20080381B1 (fr)
LT (3) LT3666797T (fr)
LU (2) LU93096I2 (fr)
MA (1) MA31978B1 (fr)
MX (3) MX375117B (fr)
MY (3) MY199053A (fr)
NL (1) NL300818I2 (fr)
NO (3) NO2016010I1 (fr)
NZ (1) NZ584101A (fr)
PE (8) PE20180173A1 (fr)
PH (2) PH12013502285B1 (fr)
PL (2) PL3666797T3 (fr)
PT (1) PT3666797T (fr)
RS (2) RS64295B1 (fr)
SG (2) SG10201710183TA (fr)
SI (2) SI2215124T2 (fr)
TN (1) TN2010000063A1 (fr)
TW (7) TWI633122B (fr)
UA (1) UA127402C2 (fr)
WO (1) WO2009026558A1 (fr)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE551363T1 (de) 2000-05-26 2012-04-15 Immunex Corp Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen
KR101036126B1 (ko) * 2006-05-11 2011-05-23 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2083861A4 (fr) 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonistes de pcsk9
EP2641917B1 (fr) 2007-08-23 2020-05-06 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2615113A3 (fr) 2007-08-23 2013-11-13 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
BRPI0907008A2 (pt) * 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JP5894913B2 (ja) * 2009-06-15 2016-03-30 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
WO2011028938A1 (fr) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
NZ620441A (en) * 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
US20120219558A1 (en) * 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
CN102639150A (zh) * 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
WO2011053743A1 (fr) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Dosage immunologique de pcsk9
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US9181538B1 (en) 2010-01-12 2015-11-10 Karen A. Norris Kexin-based vaccines to prevent or treat fungal infections
WO2011087934A2 (fr) * 2010-01-12 2011-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Vaccins dérivés de kexine destinés à prévenir ou traiter des infections fongiques
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2650016A1 (fr) * 2011-01-28 2013-10-16 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
RU2604139C2 (ru) * 2011-01-28 2016-12-10 Санофи Байотекнолоджи Фармацевтические композиции, содержащие антитела к pcsk9 человека
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US20130315927A1 (en) * 2011-02-11 2013-11-28 Novartis Ag Pcsk9 antagonists
EP3604330A1 (fr) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Anticorps fc spécifique au fcgammariib
PT3415619T (pt) 2011-04-28 2021-03-22 Univ Leland Stanford Junior Identificação de polinucleótidos associados a uma amostra
JP6081714B2 (ja) * 2011-04-28 2017-02-15 株式会社ビー・エム・エル 高コレステロール血症と動脈硬化の検出方法
AR088782A1 (es) * 2011-04-29 2014-07-10 Sanofi Sa Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (fr) * 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
WO2012170607A2 (fr) * 2011-06-10 2012-12-13 Novartis Ag Utilisation d'antagonistes de pcsk9
DK2728002T3 (da) 2011-06-30 2022-04-04 Chugai Pharmaceutical Co Ltd Heterodimeriseret polypeptid
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) * 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
US9987428B2 (en) 2011-10-14 2018-06-05 Amgen Inc. Injector and method of assembly
US20140228539A1 (en) * 2011-10-21 2014-08-14 Tanvex Biologics Corp. Separation of acetylated proteins from unacetylated proteins
SG10201609301QA (en) 2011-11-30 2016-12-29 Chugai Pharmaceutical Co Ltd Drug containing carrier into cell for forming immune complex
EP2837685B1 (fr) 2012-04-09 2020-09-09 Daiichi Sankyo Company, Limited Anticorps anti-fgfr2
US9321681B2 (en) * 2012-04-27 2016-04-26 United States Gypsum Company Dimensionally stable geopolymer compositions and method
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
EP2667197B1 (fr) 2012-05-25 2015-09-16 Zora Biosciences OY Biomarqueurs à efficacité et spécificité sensibles pour l'inhibition de proprotéine convertase de subtilisine/kexin de type 9 (PCSK9)
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
NZ704771A (en) 2012-08-13 2018-02-23 Regeneron Pharma Anti-pcsk9 antibodies with ph-dependent binding characteristics
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
NZ709013A (en) 2012-12-05 2020-01-31 Alnylam Pharmaceuticals Inc Pcsk9 irna compositions and methods of use thereof
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
US10287317B2 (en) * 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
US20160039945A1 (en) * 2013-03-15 2016-02-11 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
WO2014149699A1 (fr) * 2013-03-15 2014-09-25 Eli Lilly And Company Protéine bifonctionnelle
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
US10850037B2 (en) 2013-03-22 2020-12-01 Amgen Inc. Injector and method of assembly
KR102318483B1 (ko) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Ｆｃ영역 개변체
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP6417118B2 (ja) * 2013-05-31 2018-10-31 株式会社ビー・エム・エル Ｐｃｓｋ９測定用標準物質
EP3004171B1 (fr) 2013-06-07 2021-10-13 Regeneron Pharmaceuticals, Inc. Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de pcsk9
EP2862877A1 (fr) 2013-10-18 2015-04-22 Sanofi Procédés pour inhiber l'athérosclérose par l'administration d'un inhibiteur de PCSK9
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
EP3013422A1 (fr) * 2013-06-28 2016-05-04 Amgen Inc. Procédés de traitement d'une hypercholestérolémie familiale homozygote
WO2015035215A1 (fr) 2013-09-05 2015-03-12 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
CN118105481A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
FR3014695A1 (fr) * 2013-12-17 2015-06-19 Kymab Ltd
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
EP2975058A1 (fr) * 2014-07-15 2016-01-20 Kymab Limited Anticorps pour leur utilisation dans le traitement de maladies liées à certains variants spécifiques de PCSK9 dans certaines populations spécifiques de patients
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2886558A1 (fr) * 2013-12-17 2015-06-24 Kymab Limited Anticorps pour une utilisation dans le traitement de maladies liées à des variants spécifiques de PCSK9 dans des populations de patients spécifiques
GB2521356B (en) * 2013-12-17 2018-10-10 Kymab Ltd Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015092393A2 (fr) * 2013-12-17 2015-06-25 Kymab Limited Cibles humaines
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
DK3089822T3 (da) 2013-12-30 2022-05-02 Atreca Inc Analyse af nukleinsyrer associeret med enkelte celler under anvendelse af nukleinsyrestregkoder
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
WO2015200438A1 (fr) * 2014-06-24 2015-12-30 Eleven Biotherapeutics, Inc. Anticorps de haute affinité contre pcsk9
EP3169710A1 (fr) * 2014-07-14 2017-05-24 Amgen Inc. Formulations d'anticorps cristallins
EP3169709B1 (fr) * 2014-07-14 2021-05-12 Amgen Inc. Formulations d'anticorps cristallines
DE202015009002U1 (de) 2014-07-15 2016-08-18 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP2975059A1 (fr) * 2014-07-15 2016-01-20 Kymab Limited Anticorps pour utilisation dans le traitement de maladies liées à certains variants spécifiques de pcsk9 dans certaines populations spécifiques de patients
EP4328245A3 (fr) 2014-07-15 2024-06-05 Kymab Ltd. Anticorps utilisés dans le traitement de pathologies associées à des variants pcsk9 spécifiques dans des populations de patients spécifiques
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
ES2847311T3 (es) 2014-08-05 2021-08-02 MabQuest SA Reactivos inmunológicos que se unen a PD-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016020799A1 (fr) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Méthodes pour réduire le cholestérol ldl
US20170224816A1 (en) 2014-08-06 2017-08-10 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016023916A1 (fr) 2014-08-12 2016-02-18 Kymab Limited Traitement de maladie par la liaison d'un ligand à des cibles présentant un intérêt
US9657099B2 (en) 2014-09-16 2017-05-23 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
WO2016071701A1 (fr) 2014-11-07 2016-05-12 Kymab Limited Traitement de maladie par liaison de ligand à des cibles d'intérêt
TWI779010B (zh) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
CN105461809B (zh) 2015-02-11 2018-10-12 康融东方（广东）医药有限公司 Pcsk9抗体、其药物组合物及其用途
CN108025063A (zh) 2015-03-10 2018-05-11 索伦托治疗有限公司 结合psma的抗体治疗剂
CN107531798B (zh) * 2015-03-20 2022-02-18 奥胡斯大学 Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
AU2016248997B2 (en) * 2015-04-15 2019-03-07 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
CN105037554B (zh) * 2015-06-12 2019-04-12 成都贝爱特生物科技有限公司 抗人pcsk9抗体的制备及其用途
PL3337828T3 (pl) 2015-08-18 2026-01-26 Regeneron Pharmaceuticals, Inc. Przeciwciała hamujące anty-pcsk9 do leczenia pacjentów z hiperlipidemią poddawaną aferezie lipoproteinowej
EP3356415B1 (fr) 2015-09-29 2024-05-01 Amgen Inc. Inhibiteurs de l'asgr pour réduire les taux de cholestérol
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105348390B (zh) * 2015-10-26 2018-08-28 北京智仁美博生物科技有限公司 抗人pcsk9单克隆抗体
US20180363000A1 (en) * 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
WO2017110981A1 (fr) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
MX2018007925A (es) * 2015-12-31 2018-08-29 Jiangsu Hengrui Medicine Co Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
CN107531795B (zh) 2016-01-05 2021-01-19 江苏恒瑞医药股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
DK3964529T3 (da) 2016-01-22 2025-06-30 MabQuest SA Ikke-blokerende pd1-specifikke antistoffer
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2017163049A1 (fr) 2016-03-21 2017-09-28 Kymab Limited Anticorps anti-paludéens qui se lient à la protéine circumsporozoïte
US11066464B2 (en) 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
CN107266575B (zh) * 2016-04-07 2021-12-24 天士力生物医药股份有限公司 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
EP3458988B1 (fr) 2016-05-16 2023-10-18 Amgen Inc. Chiffrement de données dans des dispositifs médicaux à capacité de calcul limitée
CN107474140B (zh) * 2016-06-08 2022-06-03 常州博嘉生物医药科技有限公司 Pcsk9特异性的结合蛋白mv072及其应用
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
WO2018029474A2 (fr) 2016-08-09 2018-02-15 Kymab Limited Anticorps anti-icos
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
JP2020502991A (ja) * 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
TWI782920B (zh) * 2016-09-20 2022-11-11 中國大陸商上海藥明生物技術有限公司 新型抗-pcsk9抗體
EP3522918A1 (fr) 2016-10-06 2019-08-14 Amgen Inc. Formulations pharmaceutiques de protéines à viscosité réduite
WO2018075792A1 (fr) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Méthodes d'abaissement de niveaux de glycémie
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
CN108239150A (zh) * 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3582825A1 (fr) 2017-02-17 2019-12-25 Amgen Inc. Dispositif d'administration de médicament à trajet d'écoulement de fluide stérile et procédé d'assemblage associé
EP3582806B1 (fr) 2017-02-20 2023-07-26 Dragonfly Therapeutics, Inc. Protéines se liant à her2, nkg2d et cd16
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CA3056011A1 (fr) 2017-03-14 2018-09-20 Amgen Inc. Controle des glycoformes afucosylees totales d'anticorps produits en culture cellulaire
US11607227B2 (en) 2017-03-21 2023-03-21 Teleflex Medical Incorporated Surgical clip and clip applier
US12023041B2 (en) 2017-03-21 2024-07-02 Teleflex Medical Incorporated Clip applier
WO2018222186A1 (fr) * 2017-05-31 2018-12-06 North Carolina Central University Optimisation d'un dosage de pcsk9 actif
CN107029243A (zh) * 2017-06-08 2017-08-11 厦门大学 一种多肽桥连的双酰腙连接键应用于醛衍生药物的递送
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
JP7242562B2 (ja) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法
EP4085942A1 (fr) 2017-07-25 2022-11-09 Amgen Inc. Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
EP3668567B1 (fr) 2017-08-18 2026-02-18 Amgen Inc. Injecteur portable avec patch adhésif stérile
JP6913566B2 (ja) * 2017-08-23 2021-08-04 協同油脂株式会社 グリース組成物
WO2019070472A1 (fr) 2017-10-04 2019-04-11 Amgen Inc. Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
MA50904A (fr) 2017-11-16 2020-09-23 Amgen Inc Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
WO2019152599A1 (fr) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Anticorps monoclonaux d'acide nucléique ciblant pcsk9 et procédés d'utilisation
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CN112040971A (zh) 2018-02-08 2020-12-04 蜻蜓疗法股份有限公司 涉及激活天然杀伤细胞的多特异性结合蛋白的癌症联合疗法
PE20211224A1 (es) * 2018-02-20 2021-07-06 Dragonfly Therapeutics Inc Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CA3093853A1 (fr) 2018-03-26 2019-10-03 Amgen Inc. Glycoformes afucosylees totales d'anticorps produits en culture cellulaire
IL316596A (en) 2018-03-30 2024-12-01 Amgen Inc C-terminal antibody variants
MX2020013155A (es) 2018-06-05 2021-04-29 Anji Pharma Us Llc Composiciones y metodos para tratar la pancreatitis.
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
SG11202100883SA (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
SG11202003531WA (en) 2018-08-10 2020-05-28 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
CN112867451B (zh) 2018-09-26 2025-06-06 泰利福医疗公司 具有稳定构件的施夹器
JP7627216B2 (ja) * 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター ムチン－１６に対する抗体およびそれを使用する方法
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CN109776680B (zh) * 2019-01-25 2020-05-12 浙江蓝盾药业有限公司 抗人pcsk9单克隆抗体及其用途
EP3969475A4 (fr) 2019-05-15 2023-04-26 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à un antigène, composition pharmaceutique et procédé
MX2021014015A (es) 2019-05-17 2022-02-21 Regeneron Pharma Metodos basados en el genoma para reducir el riesgo cardiovascular.
WO2021050989A1 (fr) * 2019-09-13 2021-03-18 Duke University Anticorps zika et leur utilisation
WO2021058597A1 (fr) 2019-09-24 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de détermination du risque d'apparition de plaques artérielles chez un sujet
GB201913846D0 (en) 2019-09-25 2019-11-06 King S College London Biomarker
CN114450593A (zh) 2019-09-26 2022-05-06 美国安进公司 产生抗体组合物的方法
WO2021098720A1 (fr) * 2019-11-18 2021-05-27 康融东方（广东）医药有限公司 Anticorps anti-pcsk9 et son utilisation
JP7709436B2 (ja) 2019-11-29 2025-07-16 カイマブ・リミテッド 生理学的鉄過剰の処置
CN115135671B (zh) * 2019-12-20 2026-01-02 新石生物制药有限公司 抗白介素-23 p19的抗体及其使用方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
PE20231851A1 (es) 2020-05-06 2023-11-21 Dragonfly Therapeutics Inc Proteinas que se unen a nkg2d, cd16 y clec12a
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
WO2022081824A1 (fr) 2020-10-15 2022-04-21 Amgen Inc. Glycanes relatifs non appariés dans des procédés de production d'anticorps
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
WO2022207785A1 (fr) 2021-03-31 2022-10-06 Kymab Limited Anticorps dirigés contre gfral
CA3215737A1 (fr) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Inhibiteurs therapeutiques de la signalisation gdf15
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AR126089A1 (es) 2021-06-07 2023-09-13 Amgen Inc Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
CN113480650B (zh) * 2021-06-30 2022-01-28 徐州医科大学 一种全人源靶向cd276的car-t细胞的制备方法及应用
WO2023059607A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de récepteur fc-gamma et teneur en glycane
WO2023076419A2 (fr) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Anticorps de sars-cov-2 et méthodes d'utilisation
CN116948030B (zh) 2022-04-25 2024-11-19 武汉大学 抗asgr1单克隆抗体及其应用
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2023222854A1 (fr) 2022-05-18 2023-11-23 Kymab Limited Utilisations d'anticorps anti-icos
WO2024220916A1 (fr) 2023-04-20 2024-10-24 Amgen Inc. Procédés de détermination de teneur relative en glycane non apparié
WO2025036347A1 (fr) * 2023-08-14 2025-02-20 信立泰(成都)生物技术有限公司 Procédé de traitement ou de prévention de maladies liées au cholestérol à l'aide d'un inhibiteur de pcsk9
WO2025038600A1 (fr) 2023-08-14 2025-02-20 Amgen Inc. Procédés de réduction de couleur jaune
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US896507A (en) 1908-04-06 1908-08-18 Theodore J Asch Sweat-band.
US1063008A (en) 1913-03-15 1913-05-27 William E Budd Vehicle-tire.
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5612114B2 (fr) 1974-06-07 1981-03-18
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2089661C (fr) 1990-08-29 2007-04-03 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (fr) 1991-12-13 1993-06-24 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2124967C (fr) 1991-12-17 2008-04-08 Nils Lonberg Animaux transgeniques non humains capables de produire des anticorps heterologues
WO1994000569A1 (fr) 1992-06-18 1994-01-06 Genpharm International, Inc. Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
AU4228997A (en) 1996-07-09 1998-02-02 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US20060246483A1 (en) * 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20070224663A1 (en) * 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20070015696A1 (en) * 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US20060223088A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US20080103090A1 (en) * 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20070055056A1 (en) * 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US20060223090A1 (en) * 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US6252050B1 (en) 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
FR2784749B1 (fr) 1998-10-14 2000-12-29 Instruments Sa Appareil de caracterisation optique de materiau en couche mince
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
GB2343233A (en) 1998-10-28 2000-05-03 Whitnash Plc Torsional vibration damper.
NL1011069C2 (nl) 1999-01-19 2000-07-20 Well Engineering Partners B V Werkwijze en installatie voor het inbrengen van een buis in een boorgat in de aardbodem.
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1514933A1 (fr) * 1999-07-08 2005-03-16 Research Association for Biotechnology Protéine sécrétoire ou protéine de membrane
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030119038A1 (en) * 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US20100291099A1 (en) * 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US7029895B2 (en) * 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20020081679A1 (en) * 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
AU1099601A (en) 1999-10-22 2001-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20110230392A1 (en) * 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
CA2399727A1 (fr) 2000-02-07 2001-08-09 Millennium Pharmaceuticals, Inc. Nouveaux homologues de type subtilase (narc-1)
JP3753917B2 (ja) 2000-03-17 2006-03-08 茨木精機株式会社 包装体の整列搬出方法及びその装置
AU5943201A (en) 2000-05-03 2001-11-12 Amgen Inc Modified peptides as therapeutic agents
JP2004515217A (ja) 2000-06-16 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
WO2002014358A2 (fr) 2000-08-11 2002-02-21 Eli Lilly And Company Nouvelles proteines secretees et leurs utilisations
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2002046383A2 (fr) 2000-12-08 2002-06-13 Incyte Genomics, Inc. Molecules de modification et de maintenance proteiques
CA2441755A1 (fr) 2001-03-21 2003-05-08 Human Genome Sciences, Inc. Proteines secretees humaines
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023243A1 (en) * 2001-06-13 2004-02-05 Yue Henry Proteases
EP1423428B2 (fr) 2001-06-20 2012-11-14 Fibron Ltd. Anticorps bloquant l'activation de fgfr3, procedes de criblage et utilisations associes
US20040038242A1 (en) * 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
US20040009178A1 (en) 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EA033750B1 (ru) 2002-09-06 2019-11-21 Amgen Inc Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
WO2004055164A2 (fr) 2002-12-13 2004-07-01 Abgenix, Inc. Systeme et methode de stabilisation d'anticorps au moyen d'histidine
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1471152A1 (fr) * 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia
CA2526398C (fr) * 2003-05-21 2014-07-15 Medarex, Inc. Anticorps monoclonaux humains diriges contre l'antigene protecteur de bacillus anthracis
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
WO2006020676A2 (fr) 2004-08-10 2006-02-23 Isis Pharmaceuticals, Inc. Methodes pour moduler des taux de cholesterol et de lipoproteine chez des humains
US20060147945A1 (en) * 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7682981B2 (en) * 2005-01-27 2010-03-23 Contour Semiconductor, Inc. Topography transfer method with aspect ratio scaling
WO2006124269A2 (fr) 2005-05-16 2006-11-23 Amgen Fremont Inc. Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
WO2007074880A1 (fr) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
JP2009524434A (ja) 2006-01-26 2009-07-02 エイチエックス・ダイアグノスティックス・インコーポレイテッド トリインフルエンザウイルス亜型ｈ５ヘマグルチニンに結合するモノクローナル抗体およびそれらの使用
EP2348106B1 (fr) 2006-05-08 2014-07-02 Adaerata, Limited Partnership Protéines chimères, cellules les comprenant et analyses les utilisant
KR101036126B1 (ko) * 2006-05-11 2011-05-23 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자의 발현을 억제하기 위한 조성물 및 방법
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008042383A1 (fr) 2006-10-02 2008-04-10 Armstrong World Industries, Inc. Procédé de préparation de polyesters de poids moléculaire élevé
US20100068194A1 (en) * 2006-10-24 2010-03-18 Dong-Ku Kim Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
CA2667869A1 (fr) * 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
EP2083861A4 (fr) * 2006-11-07 2010-11-24 Merck Sharp & Dohme Antagonistes de pcsk9
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
EP2106261A4 (fr) 2006-11-07 2010-05-26 Merck Sharp & Dohme Antagonistes de pcsk9
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
JP5086618B2 (ja) * 2006-11-27 2012-11-28 オリンパス株式会社 カプセル型内視鏡
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
TW200838551A (en) 2006-11-27 2008-10-01 Isis Pharmaceuticals Inc Methods for treating hypercholesterolemia
EP2114451A2 (fr) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Préparations d'anticorps ant-il-13 et leurs utilisations
WO2008109871A2 (fr) 2007-03-08 2008-09-12 Irm Llc Structure cristalline de proprotéine convertase 9 (pcsk9) et utilisations de celle-ci
KR20100019440A (ko) * 2007-04-13 2010-02-18 노파르티스 아게 프로-단백질 전환효소 서브틸리신/켁신 유형 ９ (ｐｃｓｋ９)를 조정하기 위한 분자 및 방법
EP2185594B1 (fr) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanisés qui se lient à ephb4
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP2641917B1 (fr) 2007-08-23 2020-05-06 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
EP2615113A3 (fr) 2007-08-23 2013-11-13 Amgen Inc. Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
WO2009055783A2 (fr) * 2007-10-26 2009-04-30 Schering Corporation Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
BRPI0907008A2 (pt) * 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
EP2250199B1 (fr) 2008-02-07 2015-09-02 Merck Sharp & Dohme Corp. Anticorps anti-tslpr modifies
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
HUE067049T2 (hu) 2008-04-11 2024-09-28 Chugai Pharmaceutical Co Ltd Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula
EP2296694B1 (fr) * 2008-04-23 2015-08-05 Amgen Inc. Variants neutralisants de la proprotéine convertase subtilisine/kexine de type 9 (pcsk9) et ses applications
CA2729961C (fr) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Anticorps anti-lingo, li113, li62 variant co2
DE102008034203B4 (de) * 2008-07-21 2018-04-26 Airbus Helicopters Deutschland GmbH Herstellung von Faserverbundbauteilen mit Formkernen
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8357371B2 (en) * 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
US8210622B2 (en) 2009-03-13 2012-07-03 Liberty Hardware Mfg. Corp. Adjustable product display assembly
WO2011028938A1 (fr) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
AU2010306415A1 (en) 2009-10-15 2012-05-03 Monash University Affinity ligands and methods for protein purification
CN102639150A (zh) 2009-10-30 2012-08-15 默沙东公司 Ax213和ax132 pcsk9拮抗剂和变体
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
WO2011053743A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Dosage immunologique de pcsk9
US8802827B2 (en) * 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
MY165614A (en) 2009-11-20 2018-04-18 Biocon Ltd Formulations of antibody
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
EP3424949A1 (fr) * 2010-04-13 2019-01-09 Bristol-Myers Squibb Company Échafaudages des domaines de la protéine de fibronectine se liant au pcsk9
CN201712554U (zh) 2010-07-14 2011-01-19 李辉 电动汽车热管理系统
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012064792A2 (fr) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation
US8613308B2 (en) 2010-12-10 2013-12-24 Uop Llc Process for transferring heat or modifying a tube in a heat exchanger
AU2011348232A1 (en) 2010-12-22 2013-07-18 Genentech, Inc. Anti-PCSK9 antibodies and methods of use
RU2604139C2 (ru) 2011-01-28 2016-12-10 Санофи Байотекнолоджи Фармацевтические композиции, содержащие антитела к pcsk9 человека
EP2650016A1 (fr) 2011-01-28 2013-10-16 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement basés sur des régimes de dosage particuliers (11565)
EP2481758A1 (fr) 2011-01-28 2012-08-01 Sanofi Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers (11566)
US20130315927A1 (en) 2011-02-11 2013-11-28 Novartis Ag Pcsk9 antagonists
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
WO2012170607A2 (fr) 2011-06-10 2012-12-13 Novartis Ag Utilisation d'antagonistes de pcsk9
CN103717615A (zh) 2011-06-20 2014-04-09 霍夫曼-拉罗奇有限公司 结合pcsk9的多肽及使用方法
BR112014000392A2 (pt) 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
WO2013091103A1 (fr) 2011-12-20 2013-06-27 Adaerata, Limited Partnership Anticorps à domaine unique en tant qu'inhibiteurs de pcsk9
WO2013148284A1 (fr) 2012-03-29 2013-10-03 Genentech, Inc. Anticorps qui se lient à un site de clivage de pcsk9 et leurs procédés d'utilisation
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9266961B2 (en) 2012-06-15 2016-02-23 Genentech, Inc. Anti-PCSK9 antibodies, formulations, dosing, and methods of use
EP2703009A1 (fr) 2012-08-31 2014-03-05 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
EP2706070A1 (fr) 2012-09-06 2014-03-12 Sanofi Traitements combinés impliquant des anticorps de la PCSK9 humaine
US20160039945A1 (en) 2013-03-15 2016-02-11 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016046684A1 (fr) 2014-09-23 2016-03-31 Pfizer Inc. Traitement avec des anticorps anti-pcsk9
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly
DE102023206495B3 (de) 2023-07-07 2024-11-21 Volkswagen Aktiengesellschaft Integrierter Schaltkreis, Anordnung sowie Verfahren zum Einkoppeln von optischen Signalen in einen integrierten Schaltkreis

Also Published As

Publication number Publication date
US8871913B2 (en) 2014-10-28
US9493576B2 (en) 2016-11-15
KR20170012592A (ko) 2017-02-02
US20130245235A1 (en) 2013-09-19
PL2215124T5 (pl) 2023-11-20
MY180102A (en) 2020-11-22
PE20180173A1 (es) 2018-01-22
CY2016023I2 (el) 2017-04-26
TW201716444A (zh) 2017-05-16
AR068011A1 (es) 2009-10-28
DE19207796T1 (de) 2022-03-10
AU2008288791B2 (en) 2014-10-30
KR20230080496A (ko) 2023-06-07
KR20260006647A (ko) 2026-01-13
US8030457B2 (en) 2011-10-04
US9056915B2 (en) 2015-06-16
CN101932607B (zh) 2014-06-25
TWI441833B (zh) 2014-06-21
HRP20160494T4 (hr) 2023-10-27
BRPI0816117B8 (pt) 2021-05-25
HRP20160494T1 (hr) 2016-06-03
SG10201710183TA (en) 2018-01-30
FI3666797T3 (fi) 2023-05-25
SG184702A1 (en) 2012-10-30
US20120251544A1 (en) 2012-10-04
US20110027287A1 (en) 2011-02-03
CY1117940T1 (el) 2017-04-26
JP2020058376A (ja) 2020-04-16
PL2215124T3 (pl) 2016-08-31
US20090142352A1 (en) 2009-06-04
MX2010001921A (es) 2010-03-11
ES2946083T3 (es) 2023-07-12
TW202330625A (zh) 2023-08-01
PL3666797T3 (pl) 2023-08-28
IL317213A (en) 2025-01-01
IL252616A0 (en) 2017-07-31
LU93180I2 (fr) 2016-10-18
US20140357853A1 (en) 2014-12-04
US9920134B2 (en) 2018-03-20
EP2215124B9 (fr) 2023-12-27
US20130079501A1 (en) 2013-03-28
PE20140231A1 (es) 2014-03-08
JP2023071833A (ja) 2023-05-23
FR16C0025I2 (fr) 2018-06-08
NO2023012I1 (no) 2023-03-20
NO2016010I1 (no) 2016-06-03
NO2016015I1 (no) 2016-08-12
JP2015166345A (ja) 2015-09-24
EA032106B1 (ru) 2019-04-30
CA2696252C (fr) 2016-06-14
CN104311665A (zh) 2015-01-28
CY2016029I2 (el) 2017-04-26
US20120020976A1 (en) 2012-01-26
JP6638009B2 (ja) 2020-01-29
KR20140064962A (ko) 2014-05-28
CY2016029I1 (el) 2017-04-26
ES2917423T3 (es) 2022-07-08
ES2573258T3 (es) 2016-06-06
HUS1600036I1 (hu) 2016-10-28
PH12013502285B1 (en) 2024-04-12
NL300818I2 (fr) 2016-07-14
JP5705288B2 (ja) 2015-04-22
DK3666797T3 (da) 2023-05-30
SI2215124T2 (sl) 2023-11-30
US20120213797A1 (en) 2012-08-23
CN112390889A (zh) 2021-02-23
KR101702194B1 (ko) 2017-02-03
US8168762B2 (en) 2012-05-01
HRP20230503T3 (hr) 2023-09-15
CN104311666A (zh) 2015-01-28
PE20131400A1 (es) 2013-12-16
LTC2215124I2 (lt) 2023-04-25
US20140357850A1 (en) 2014-12-04
IL252616B (en) 2020-05-31
FI2215124T4 (fi) 2023-10-10
TW201500376A (zh) 2015-01-01
IL304868A (en) 2023-10-01
US8563698B2 (en) 2013-10-22
KR20100057070A (ko) 2010-05-28
CO6230997A2 (es) 2010-12-20
JP5906333B2 (ja) 2016-04-20
CN113402611A (zh) 2021-09-17
TW201500374A (zh) 2015-01-01
US20130085265A1 (en) 2013-04-04
TWI799416B (zh) 2023-04-21
PH12013502285A1 (en) 2016-08-08
US20130079502A1 (en) 2013-03-28
US8889834B2 (en) 2014-11-18
PE20140220A1 (es) 2014-02-21
JOP20080381B1 (ar) 2023-03-28
SI3666797T1 (sl) 2023-10-30
JP2016182114A (ja) 2016-10-20
TWI675848B (zh) 2019-11-01
US20140228557A1 (en) 2014-08-14
ES2573258T5 (es) 2024-02-23
SI2215124T1 (sl) 2016-09-30
PE20221507A1 (es) 2022-10-04
US20140235830A1 (en) 2014-08-21
KR20220031734A (ko) 2022-03-11
RS64295B1 (sr) 2023-07-31
CL2008002495A1 (es) 2009-09-04
CN112409489A (zh) 2021-02-26
TWI675846B (zh) 2019-11-01
KR101494932B1 (ko) 2015-02-26
BR122018012430B1 (pt) 2019-10-08
KR20180035947A (ko) 2018-04-06
BRPI0816117B1 (pt) 2018-12-18
LTPA2016021I1 (lt) 2016-06-27
US20120093818A1 (en) 2012-04-19
US20140235831A1 (en) 2014-08-21
EP3666797A1 (fr) 2020-06-17
IL204013B2 (en) 2025-07-01
LT3666797T (lt) 2023-08-10
TWI890005B (zh) 2025-07-11
TW200916481A (en) 2009-04-16
FR16C0025I1 (fr) 2016-07-08
IL273353A (en) 2020-05-31
JP2010536384A (ja) 2010-12-02
LTPA2016025I1 (lt) 2016-09-12
US20090326202A1 (en) 2009-12-31
TW201906871A (zh) 2019-02-16
CN104311667A (zh) 2015-01-28
PE20091006A1 (es) 2009-08-14
UA127402C2 (uk) 2023-08-16
BRPI0816117A2 (pt) 2015-03-10
TW201500375A (zh) 2015-01-01
IL273353B1 (en) 2023-09-01
CN112415203A (zh) 2021-02-26
EP3666797B1 (fr) 2023-05-17
MX375117B (es) 2025-03-06
MX2020008898A (es) 2020-10-12
PT3666797T (pt) 2023-06-07
KR20210028741A (ko) 2021-03-12
WO2009026558A1 (fr) 2009-02-26
JP2014043446A (ja) 2014-03-13
MY199053A (en) 2023-10-11
JP2018118974A (ja) 2018-08-02
LU93096I2 (fr) 2016-08-01
US20120020975A1 (en) 2012-01-26
US20120027765A1 (en) 2012-02-02
PE20140014A1 (es) 2014-01-31
EP2215124B2 (fr) 2023-07-19
KR20240113594A (ko) 2024-07-22
DK2215124T3 (en) 2016-05-30
HUE028162T2 (en) 2016-12-28
NZ584101A (en) 2012-09-28
US8859741B2 (en) 2014-10-14
EP2215124B1 (fr) 2016-02-24
CN101932607A (zh) 2010-12-29
HUE062493T2 (hu) 2023-11-28
US20130052201A1 (en) 2013-02-28
PH12013502286A1 (en) 2016-02-22
MA31978B1 (fr) 2011-01-03
US20140357854A1 (en) 2014-12-04
EP3202791A1 (fr) 2017-08-09
HUS1600029I1 (hu) 2016-09-28
MY199051A (en) 2023-10-11
CR11328A (es) 2010-07-12
DE202008018562U1 (de) 2015-11-02
US8829165B2 (en) 2014-09-09
DK3666797T5 (da) 2024-08-26
BR122018012430B8 (pt) 2021-07-27
US20130058944A1 (en) 2013-03-07
CA2696252A1 (fr) 2009-02-26
EA201000356A1 (ru) 2010-08-30
HK1143824A1 (zh) 2011-01-14
TWI633122B (zh) 2018-08-21
US20140357851A1 (en) 2014-12-04
PE20140221A1 (es) 2014-02-21
DE19207796T9 (de) 2023-02-23
US8981064B2 (en) 2015-03-17
EP2215124A1 (fr) 2010-08-11
US8883983B2 (en) 2014-11-11
US20140228547A1 (en) 2014-08-14
IL273353B2 (en) 2024-01-01
RS54756B2 (sr) 2024-07-31
RS54756B1 (sr) 2016-10-31
JP5441905B2 (ja) 2014-03-12
IL204013A (en) 2017-07-31
US20140228545A1 (en) 2014-08-14
US20150031870A1 (en) 2015-01-29
AU2008288791A1 (en) 2009-02-26
CY2016023I1 (el) 2017-04-26
TWI675847B (zh) 2019-11-01
KR20200074262A (ko) 2020-06-24
US8871914B2 (en) 2014-10-28
US20140357852A1 (en) 2014-12-04
US20150087819A1 (en) 2015-03-26
US9045547B2 (en) 2015-06-02
DK2215124T4 (da) 2024-01-29

Similar Documents

Publication Publication Date Title
PH12013502286A1 (en) Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
EA201200861A1 (ru) Антагонисты pcsk9
CY1126125T1 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτiλισινης κεξινης τυπου 9 (pcsk9)
NZ601923A (en) High Affinity Human Antibodies to PCSK9
EP2641917A3 (fr) Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
AR110799A2 (es) Proteínas de unión a antígeno contra proproteína convertasa subtilisina / kexina tipo 9 (pcsk9)
EA201892670A1 (ru) Антигенсвязывающие белки, связывающиеся с пропротеин конвертазой субтилизин кексином тип 9 (pcsk9)